Evaluation of the safety of Feline Herpes Virus, bivalent deleted live vaccine, administered as intranasal vaccine to cats

EU record number

B/BE/04/BV1

Treated organism

cats

Indication category

prevention and/or reduction of infection caused by Feline immunodeficiency virus (FIV)

Genetic modification

gene for the env glycoprotein or gene for the gag protein of the Feline immunodeficiency virus (FIV)

Method of transfer of nucleic acid of interest

Feline Herpes Virus

Route of administration

intranasal

Locations in Belgium

Mechelen, Sint Katelijne-Waver and Schaerbeek

Nr of subjects

at least 40 animals, maximum 1000 animals

Foreseen duration

1 year

Type of procedure

Deliberate release only

Information for the public

B/BE/04/BV1 - Summary Notification Information Format (SNIF)

Public information presented according to the provisions of Directive 2001/18/EC

B/BE/04/BV1 - Public information sheet (written by the notifier)

B/BE/04/BV1 - Fiche d'information destinée au public (préparée par le notifiant)

B/BE/04/BV1 – Informatie fiche bestemd voor het publiek (voorbereid door de kennisgever)

Information related to the decision procedure

B/BE/04/BV1 - Advice Biosafety Advisory Council

15 July 2005: The Biosafety Advisory Council issues a positive advice (with conditions) for this trial.

B/BE/04/BV1 - Decision of the Federal Minister (FINAL DECISION)

1 September 2005: The Federal Minister gives a final decision (positive) for this trial, reminding the conditions requested by the Biosafety Advisory Council in its advice.